NasdaqCM - Delayed Quote USD

Aprea Therapeutics, Inc. (APRE)

0.4846 -0.0090 (-1.82%)

At close: October 30 at 4:00:01 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

GlobeNewswire 15d ago

APRE
-1.82%
Aprea Therapeutics to Present at October Conferences

GlobeNewswire 26d ago

APRE
-1.82%
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

GlobeNewswire 1mo ago

APRE
-1.82%
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire 1mo ago

APRE
-1.82%
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

GlobeNewswire 2mo ago

APRE
-1.82%
Aprea Therapeutics Announces Second Quarter 2026 Financial Results

GlobeNewswire 2mo ago

APRE
-1.82%
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

GlobeNewswire 3mo ago

APRE
-1.82%
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

GlobeNewswire 4mo ago

APRE
-1.82%
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

GlobeNewswire 5mo ago

APRE
-1.82%
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

GlobeNewswire 6mo ago

APRE
-1.82%
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

GlobeNewswire 6mo ago

APRE
-1.82%
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

GlobeNewswire 6mo ago

APRE
-1.82%

Performance Overview

Return	APRE	S&P 500 (^GSPC)
YTD	-43.19%	+10.73%
1-Year	-66.58%	+11.11%
3-Year	-86.44%	+81.91%

U.S. markets closed

Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

Aprea Therapeutics to Present at October Conferences

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement